Real-World data tests Drug's 3-Year impact on rare brain disorder

This study aims to see if the drug troriluzole can slow the progression of spinocerebellar ataxia (SCA), a rare genetic disorder that affects movement and coordination, over three years. It compares data from about 909 people who took the drug in a previous long-term study to data from similar patients who did not receive the drug, using existing medical records. The main goal is to determine if the drug helps patients worsen more slowly than they would without treatment.